The Stem Cell, the Small Molecule, and the Neurodegenerative Disease

Posted on 2021-01-13

Neurodegenerative diseases are a group of disorders characterised by progressive neuronal cell loss and apoptosis; a key pathological feature of most conditions is the accumulation of misfolded proteins, resulting in neuronal dysfunction. Common diseases include Parkinson’s disease (PD), Alzheimer’s disease (AD), and Huntington’s disease (HD). Whilst extensive research over the years has founded a comprehensive understanding of the complex cellular mechanisms and pathways that underpin neuronal pathologies, there remains no effective therapy to prevent or treat the disease.

The current lack of treatment is primarily due to the limited abilities of neuronal cells for self-renewal and regeneration. Enter, the stem cell. The different classes of stem cells include embryonic stem (ES) cells, progenitor cells, mesenchymal stem cells (MSCs), and induced pluripotent stem (iPS) cells. Each stem cell type exhibits certain qualities and advantages, and with their potential for proliferation and multi-lineage differentiation they are exciting candidates for treating neurodegenerative disease. 

With the tools to modulate key signaling pathways, cell proliferation and differentiation, the therapeutic applications of stem cells can be explored. The future of research into stem-cell based therapies relies on the use of small molecules that can act as stem cell modulators.

Abbexa is proud to offer an extensive range of Small Molecules to support you in your research into Stem Cell-Based Therapies for Neurodegenerative Disease.

Product Highlights

  • Promotes neurogenesis; enhances the proliferation and differentiation of hippocampal subgranular zone (SGZ) neuroblasts, improving hippocampal function (memory and learning).
  • Induces robust neuronal differentiation in adult neural stem cells, through a calcium-activated signaling pathway dependent on myocyte-enhancer factor 2 (MEF2)-dependent gene expression.
  • Down-regulates malignant astrocyte character and induces their re-entry into the cell cycle, resulting in an upregulation of neuronal gene expression.
  • Potentiates cell proliferation and neuronal commitment in the hippocampal DG of adult rats.

  • Inhibits the release of pro-inflammatory mediators and reduces oxidative stress, preventing the development of neuropathic pain.
  • Neuroprotective against excitotoxicity by inhibiting the activation and proliferation of microglia.
  • Reduces Matrix metalloproteinase 9 (MMP-9) activity; MMP-9 is critical for Central Nervous System (CNS) development, and misregulated activation of the enzyme is implicated in numerous neurodegenerative disorders.

  • Induces selective neuronal differentiation of multipotent hippocampal neural progenitor cells; a useful tool to study the processes that dictate stem cell fate in vitro and in vivo.
  • Potent and selective.
  • Competitively suppresses astrocyte differentiation.

Research Articles:

Functional and mechanistic exploration of an adult neurogenesis-promoting small molecule

Small-molecule activation of neuronal cell fate

Small-molecule blocks malignant astrocyte proliferation and induces neuronal gene expression

ISX-9 can potentiate cell proliferation and neuronal commitment in the rat dentate gyrus

Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms

Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia

High MMP-9 activity levels in fragile X syndrome are lowered by minocycline

A synthetic small molecule that induces neuronal differentiation of adult hippocampal neural progenitor cells